Subscribe

Biotech Sectors

Biotech activity varies wildly by sector. Oncology is red-hot. Gene therapy is high-risk, high-reward. Rare disease offers steady approval rates with premium pricing. Here's what's happening in each sector.

Oncology

Very Hot

The hottest area in biotech. Checkpoint inhibitors, CAR-T cell therapies, and antibody-drug conjugates are driving a new wave of approvals. Personalized cancer vaccines (mRNA-based) are the next frontier.

28%
FDA Approval Rate
420
Active Trials
$2.8B
Avg Dev Cost
Key Companies:
  • MRNA (cancer vaccines)
  • GILD (ADCs)
  • REGN (bispecifics)
Key Pipeline:
  • mRNA-4157 (melanoma)
  • Trodelvy (breast cancer)
  • Linvoseltamab (myeloma)

Gene Therapy

Hot

One-time treatments that fix the genetic cause of disease. CRISPR, base editing, and AAV-delivered gene therapies. Binary risk — massive upside if they work, complete failure if they dont.

18%
FDA Approval Rate
180
Active Trials
$3.5B
Avg Dev Cost
Key Companies:
  • CRSP (CRISPR)
  • EDIT (base editing)
  • BLUE (CAR-T)
Key Pipeline:
  • Casgevy (sickle cell)
  • CTX112 (CAR-T)
  • EDIT-301 (SCD)

mRNA

Expanding

Beyond COVID: mRNA platforms are expanding into oncology (personalized cancer vaccines), rare disease, and infectious disease. The technology is proven; the application pipeline is the story.

22%
FDA Approval Rate
95
Active Trials
$2.1B
Avg Dev Cost
Key Companies:
  • MRNA (Moderna)
  • BNTX (BioNTech)
  • NVAX (protein-based)
Key Pipeline:
  • mRNA-4157 (cancer vaccine)
  • BNT122 (pancreatic)
  • mRESV (RSV)

Rare Disease

Steady

Orphan drug designations, ultra-rare indications, and the pricing power that comes with tiny patient populations. Higher approval rates, smaller markets, but premium pricing.

35%
FDA Approval Rate
240
Active Trials
$1.8B
Avg Dev Cost
Key Companies:
  • VRTX (CF)
  • ALNY (RNAi)
  • BIIB (SMA)
Key Pipeline:
  • Vanzacaftor (CF)
  • Nucapsiran (hypertension)
  • Zauratigene (SMA)

Neuroscience

Cautiously Hot

Historically the graveyard of biotech — but new mechanisms are showing promise. Alzheimer's (Leqembi), depression (Zurzuvae), and Parkinson's are leading a cautious revival.

12%
FDA Approval Rate
150
Active Trials
$4.2B
Avg Dev Cost
Key Companies:
  • BIIB (Alzheimer's)
  • SAGE (depression)
  • ACAD (Parkinson's)
Key Pipeline:
  • Leqembi (Alzheimer's)
  • Zurzuvae (PPD)
  • Nuplazid (Parkinson's)

Infectious Disease

Steady

Vaccines, antivirals, and antibiotics. Pandemic preparedness funding is a new tailwind. Lenacapavir (twice-yearly HIV PrEP) could be transformative for Gilead.

30%
FDA Approval Rate
180
Active Trials
$1.9B
Avg Dev Cost
Key Companies:
  • GILD (HIV/HBV)
  • PFE (vaccines)
  • MRNA (vaccines)
Key Pipeline:
  • Lenacapavir (HIV PrEP)
  • PAXLOVID (COVID)
  • mRESV (RSV)

Get sector updates by email